← Back to Screener
Ensysce Biosciences, Inc. Common Stock (ENSC)
Price$0.25
Value ScoreA
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-93.57%
Price vs S&P 500 (4W)-27.43%
VGM Score42.91
Market Capitalization$3.57M
All Metrics
Book Value / Share (Quarterly)$0.70
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)26.21%
Cash Flow / Share (Quarterly)$-1.05
Price vs S&P 500 (YTD)-80.54%
Net Profit Margin (TTM)-250.36%
EPS (TTM)$-3.34
10-Day Avg Trading Volume1.12M
EPS Excl Extra (TTM)$-3.34
EPS (Annual)$-3.98
ROI (Annual)-199.18%
Net Profit Margin (5Y Avg)-522.58%
Cash / Share (Quarterly)$0.08
Revenue Growth QoQ (YoY)-27.18%
ROA (Last FY)-142.62%
Revenue Growth TTM (YoY)-24.36%
EBITD / Share (TTM)$-3.02
ROE (5Y Avg)-10.24%
Operating Margin (TTM)-251.40%
Cash Flow / Share (Annual)$-5.52
P/B Ratio1.11x
P/B Ratio (Quarterly)1.04x
Net Income / Employee (Annual)$-1,272,000
EV / Revenue (TTM)0.65x
Net Interest Coverage (TTM)-541.15x
ROA (TTM)-256.59%
EV / EBITDA (TTM)6.43x
EPS Incl Extra (Annual)$-3.98
Current Ratio (Annual)2.42x
Quick Ratio (Quarterly)0.27x
3-Month Avg Trading Volume5.46M
52-Week Price Return-89.14%
Revenue / Employee (TTM)$588,500
Tangible BV / Share (Quarterly)$0.52
P/S Ratio (Annual)0.70x
Asset Turnover (Annual)0.93x
52-Week High$2.75
Operating Margin (5Y Avg)-498.67%
EPS Excl Extra (Annual)$-3.98
26-Week Price Return-85.64%
Quick Ratio (Annual)1.65x
13-Week Price Return-52.85%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)0.71x
Enterprise Value$3.07M
Asset Turnover (TTM)1.02x
Revenue / Employee (Annual)$633,300
Pretax Margin (Annual)-200.85%
Cash / Share (Annual)$2.57
3-Month Return Std Dev125.09%
Net Income / Employee (TTM)$-1,473,300
ROE (Last FY)-215.28%
Net Interest Coverage (Annual)-624.97x
EPS Basic Excl Extra (Annual)$-3.98
Receivables Turnover (TTM)427.99x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-3.34
Receivables Turnover (Annual)7.02x
ROI (TTM)-332.77%
P/S Ratio (TTM)0.76x
Pretax Margin (5Y Avg)-523.41%
Revenue / Share (Annual)$1.98
Tangible BV / Share (Annual)$-6.95
Price vs S&P 500 (52W)-113.51%
Year-to-Date Return-72.38%
5-Day Price Return-9.25%
EPS Normalized (Annual)$-3.98
ROA (5Y Avg)-217.56%
Net Profit Margin (Annual)-200.84%
Month-to-Date Return-9.57%
Cash Flow / Share (TTM)$-7.50
EBITD / Share (Annual)$-4.00
Operating Margin (Annual)-202.12%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-9.12%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.34
P/TBV (Quarterly)1.86x
P/B Ratio (Annual)2.18x
Pretax Margin (TTM)-250.37%
Book Value / Share (Annual)$2.73
Price vs S&P 500 (13W)-61.10%
Beta0.84x
Revenue / Share (TTM)$0.69
ROE (TTM)-374.96%
52-Week Low$0.23
vGradeA
gGradeD
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.52est. -0.74
Analyst Recommendations
Apr 2024
May 2024
Jun 2024
Jul 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENSCEnsysce Biosciences, Inc. Common Stock | A | D | D | $0.25 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Ensysce Biosciences is a clinical-stage biotech company developing safer opioid medications using proprietary abuse-resistant and overdose-protection technologies. The company's pipeline includes two drug platforms—the TAAP platform for abuse resistance and the MPAR platform for overdose protection—targeting the severe pain management market while reducing addiction and overdose risk. By addressing a critical unmet need, Ensysce aims to provide healthcare providers with effective pain treatment options that limit potential for drug abuse.